Αρχική World News Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with... World News Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas Από Ogkologos - 28 Απριλίου, 2025 955 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Our nurses answer your frequently asked questions about cancer 2 Μαρτίου, 2023 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... 5 Απριλίου, 2023 Can the New “Omics” on the Block Find Liver Cancer in... 15 Μαΐου, 2023 Makeup Artist Gives Breast Cancer Survivors Free Makeovers 6 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on... Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... Cómo prepararse para su exploración por TEP-TC
